First Eagle Investment Management LLC Makes New $4.63 Million Investment in Beta Bionics, Inc. $BBNX

First Eagle Investment Management LLC acquired a new stake in shares of Beta Bionics, Inc. (NASDAQ:BBNX) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 233,202 shares of the company’s stock, valued at approximately $4,634,000.

Several other large investors have also recently made changes to their positions in BBNX. Quantbot Technologies LP purchased a new stake in shares of Beta Bionics in the third quarter worth about $286,000. TD Asset Management Inc increased its stake in Beta Bionics by 50.7% in the 3rd quarter. TD Asset Management Inc now owns 60,076 shares of the company’s stock worth $1,194,000 after acquiring an additional 20,200 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Beta Bionics by 203.6% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after acquiring an additional 1,594 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Beta Bionics by 139.1% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock worth $64,000 after acquiring an additional 1,863 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Beta Bionics during the 3rd quarter valued at approximately $295,000.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BBNX. Wall Street Zen cut shares of Beta Bionics from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Robert W. Baird reduced their target price on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. Stifel Nicolaus decreased their target price on shares of Beta Bionics from $25.00 to $22.00 and set a “buy” rating on the stock in a research report on Wednesday, February 18th. Bank of America lowered Beta Bionics from a “buy” rating to a “neutral” rating in a research report on Friday, January 9th. Finally, TD Cowen initiated coverage on Beta Bionics in a research note on Monday, January 26th. They set a “hold” rating and a $17.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.20.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Recent operational/analyst context supports longer‑term upside — Beta Bionics beat EPS estimates in its Feb. 17 quarter and the consensus analyst view remains a “Moderate Buy” with a $23.20 average price target, providing a counterbalance to near‑term selling. MarketBeat coverage
• Neutral Sentiment: Short‑interest data published for early March shows implausible values (entries report “0 shares”/NaN and 0.0 days to cover), so there is no reliable signal from short sellers — treat reported short‑interest changes as inconclusive until corrected by exchanges or data providers.
• Negative Sentiment: A wave of small insider sell orders was disclosed in early March (including the CFO’s sale of 1,428 shares and several other executive sales at roughly $12.36 each). Multiple Form 4 filings and press coverage frame this as coordinated executive selling, which often pressures sentiment for small‑cap biotech/medical device stocks. TipRanks: Insiders Cash Out
• Negative Sentiment: A securities‑litigation firm (Faruqi & Faruqi, LLP) issued a shareholder reminder/investigation notice seeking investors who experienced losses, increasing legal and reputational risk and likely weighing on near‑term sentiment until the matter is clarified. GlobeNewswire: Faruqi & Faruqi notice

Insider Activity at Beta Bionics

In other Beta Bionics news, CFO Stephen Feider sold 20,000 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total value of $590,600.00. Following the transaction, the chief financial officer owned 42,614 shares of the company’s stock, valued at $1,258,391.42. This represents a 31.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Mike Mensinger sold 2,200 shares of the stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $30.10, for a total value of $66,220.00. Following the completion of the sale, the insider owned 80,752 shares in the company, valued at approximately $2,430,635.20. The trade was a 2.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 34,352 shares of company stock worth $941,569.

Beta Bionics Trading Down 1.6%

Beta Bionics stock opened at $11.38 on Thursday. Beta Bionics, Inc. has a 12-month low of $8.89 and a 12-month high of $32.71. The firm has a 50-day moving average price of $18.35 and a 200-day moving average price of $22.35. The firm has a market capitalization of $505.04 million, a PE ratio of -5.84 and a beta of 5.60.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.12. The company had revenue of $32.12 million for the quarter. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.